Neuphoria Therapeutics Inc. · NASDAQ:NEUP
Neuphoria Therapeutics — Proxy Contest (November 2025)
25 slides from Neuphoria Therapeutics's proxy contest presentation, Nov 25, 2025
Slide 1: NASDAQ: NEUP
NASDAQ: NEUP
Slide 2: Forward-Looking Statements
/ Neuphoria cautions that statements included in this presentation that are not a description of historical facts are forward - looking state ments. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “pr edi ct,” “seek,” “contemp
Slide 3: / ®ôϙÍŘôϙîôîĖèÍťôîϙťĺϙŕĖĺIJôôŘĖIJČϙæŘôÍħťēŘĺŪČēϙťēôŘÍŕĖôŜϙ ťēÍťϙÍîîŘôŜŜϙťēôϙèĺıŕīôƄϙIJôôîŜϙĺċϙĖIJîĖŽĖîŪÍīŜϙÍƯôèťôîϙæƅϙ IJô…
/ ®ôϙÍŘôϙîôîĖèÍťôîϙťĺϙŕĖĺIJôôŘĖIJČϙæŘôÍħťēŘĺŪČēϙťēôŘÍŕĖôŜϙ ťēÍťϙÍîîŘôŜŜϙťēôϙèĺıŕīôƄϙIJôôîŜϙĺċϙĖIJîĖŽĖîŪÍīŜϙÍƯôèťôîϙæƅϙ IJôŪŘĺŕŜƅèēĖÍťŘĖèϙîĖŜĺŘîôŘŜ ϟϙ By focusing on novel approaches and advancing scientific understanding, we aim to deliver medicines that offer lasting relief and hope for a brighter, heal
Slide 4: Neuphoria's Pipeline
/ Neuphoria’s Pipeline INTERNAL PARTNERED PRECLINICAL PROGRAM INDICATION DISCOVERY PRE - CLINICAL PHASE 1 PHASE 2 PHASE 3 NAM : Negative Allosteric Modulator; PAM : Positive Allosteric Modulator; ADHD : Attention Deficit Hyperactivity Disorder; CIAS : Cognitive impairment associated with schizophren
Slide 5: BNC210 (soclenicant) Program Overview
/ BNC210 (soclenicant) Program Overview
Slide 6: BNC210: A Transformative Treatment for PTSD
/ BNC210: A Transformative Treatment for PTSD A First - in - Class α7 Nicotinic Receptor Small Molecule Negative Allosteric Modulator (NAM) Novel MoA • Unique and differentiated MoA with high confidence in rationale and probabilities of success* Game - changing Product Profile • Multiple symptom rel
Slide 7: PTSD is a Complex Neuropsychiatric Disorder
/ Avoiding trauma - related: People Places Activities Nightmares Problems concentrating Sleep disturbances Irritability Aggression Social withdrawal Negative perception of self and world Repetitive unwanted memories Flashbacks Ph2b PTSD data – Thought Intrusions Cluster Enhanced conditioned fear ext
Slide 8: BNC210 Significantly Reduced PTSD Symptom Severity
/ BNC210 Significantly Reduced PTSD Symptom Severity Clinically Meaningful Treatment Effects/Effect Sizes During 12 Weeks of Treatment & Early Onset of Effect Overall Placebo BNC210 900 mg Demographics 212 106 106 Randomized Population 42.3 (19, 68) 42.4 (21, 68) 42.3 (19, 67) Age (years) - Mean (mi
Slide 9: Ph2b/3 Program Overview
/ Ph2b/3 Program • Two Cohort Design • Cohort 1: 8 - week randomized placebo - controlled design to evaluate safety and efficacy of BNC210 450 mg BID • Cohort 2: 12 - week randomized placebo - controlled design with 52 - week open label extension Consistent Protocol and Design Conduct • CAPS - 5 as
Slide 10: BNC210 Development Plan
BNC210 Development Plan Nonclinical Phase 3 Enabling NDA Enabling DP SUPPLY ($0.6M) CHRONIC TOXICITY ($2.5 - $ 3 M) MASS BALANCE STUDY ($2M) CMC CARCINOGENICITY ($1.5M+$1.5M) PROCESS DEVELOPMENT/VALIDATION ($2+$3M) ABUSE LIABILITY ($2M) Clinical Pharmacology DDI ($1M) API + DP SUPPLY ($5M) PTSD Prog
Slide 11: Merck Strategic Partnership: MK-1167 for Alzheimer's Disease
/ Merck Strategic Partnership: MK - 1167 for Alzheimer’s Disease Program Overview
Slide 12: Merck Strategic Collaboration
/ Merck Strategic Collaboration ϙ • Two α7 receptor PAM candidates in clinical development for the treatment of cognitive disorders • Candidates, MK - 4334 and MK - 1167 have shown promising profiles in multiple preclinical studies. • Merck has successfully completed multiple Phase 1 studies that as
Slide 13: / Jun 2014 щ͑͏aϙŪŕċŘĺIJťϙŕÍƅıôIJťϙĺIJϙīĖèôIJŜĖIJČϙťēôϙ ͖̊ϙ „aϙ ŕŘĺČŘÍıϙťĺϙa‹" Feb 2017 щ͐͏aϙ„ēÍŜôϙ͐ϙıĖīôŜťĺIJôϙŕÍƅıôIJťϙċĺŘϙ…
/ Jun 2014 щ͑͏aϙŪŕċŘĺIJťϙŕÍƅıôIJťϙĺIJϙīĖèôIJŜĖIJČϙťēôϙ ͖̊ϙ „aϙ ŕŘĺČŘÍıϙťĺϙa‹" Feb 2017 щ͐͏aϙ„ēÍŜôϙ͐ϙıĖīôŜťĺIJôϙŕÍƅıôIJťϙċĺŘϙƱŘŜťϙ îĺŜôϙÍîıĖIJĖŜťŘÍťĖĺIJ Apr 2022 to Nov 2022 MK - 4334 - 007 / NCT05136690 • ĖĺıÍŘħôŘϙŜťŪîƅϙĖIJϙēôÍīťēƅϙÍIJîϙŜèēĖƏĺŕēŘôIJĖèϙ ŕÍŘťĖèĖŕÍIJťŜ MK - 4334 (first clinical candidate) Other Pha
Slide 14: Carina Strategic Partnership: CNA3101 for CAR-T Cell Therapy
/ Carina Strategic Partnership: CNA3101 for CAR - T Cell Therapy Program Overview
Slide 15: Carina Biotech Strategic IP Licensing
/ Carina Biotech Strategic IP Licensing LGR5 - targeted CAR - T Cell Therapy for the Treatment of Solid Tumors ϙ • Carina Biotech’s LGR5 - targeted CAR - T cell therapy CNA3103 is currently in development for the treatment of metastatic colorectal cancer. • In January 2023, Carina announced that it
Slide 16: Summary
/ Summary • Pipeline with two clinical stage programs • BNC210 has demonstrated POC in Ph2b PTSD and Ph2 GAD • Successful regulatory interactions and pathway clarity • Strong CMC readiness, IP portfolio, blockbuster potential in PTSD • Merck collaboration validates our ion channel platform robustnes
Slide 17: Lynx1's Proxy Contest
Lynx1’s Proxy Contest Non-Confidential Corporate Deck & neuphoria
Slide 18: Dissident Actions Disrupting Strategic Review Process
/ Dissident Actions Disrupting Strategic Review Process October 20, 2025 Company announced its plan to conduct a strategic review of portfolio and business operations with the goal of maximizing value for stockholders October 23, 2025 Lynx1 Master Fund LP (“Lynx1”) filed a Schedule 13D reporting its
Slide 19: Neuphoria's Plan
/ Neuphoria’s Plan • Run a robust and uninterrupted review of strategic alternatives • Advance pipeline programs and seek to maximize stockholder value • Milestone payments and funds previously raised under existing ATM program (no ATM sales have been made since Nov. 7) will create the opportunity t
Slide 20: Neuphoria Nominees
/ Neuphoria Nominees • Key Strengths : Deep investment, transactional, and capital allocation expertise that is vital for maximizing stockholder value while reviewing strategic alternatives. Peter Miles Davies • Mr. Davies has more than 15 years of investment banking experience, principally at Roths
Slide 21: Lynx1's Board Nominees
/ Lynx1’s Board Nominees • Key Concerns : L ack of vision and understanding in the value of the Company, no expertise to navigate complex strategic alternatives and will disrupt the Company’s ongoing strategic alternatives review process, a current priority for the Company. Neither of Lynx1’s nomine
Slide 22: Corporate Governance Highlights
/ CORPORATE GOVERNANCE HIGHLIGHTS • The Audit and Risk Management Committee and the Nomination and Compensation Committee are composed entirely of independent directors. • The Board of Directors holds executive sessions solely with its independent directors. • The Board of Directors, with the assist
Slide 23: In Summary
/ IN SUMMARY • Neuphoria has laid out a clear strategy for future growth and long - term value creation whether by developing its pipeline or by a strategic transaction. Our board is uniquely positioned to execute on this strategic plan. • Neuphoria continues to be led by a strong management team an
Slide 24: Securing Neuphoria's Future: Vote FOR Neuphoria's Board Slate
SECURING NEUPHORIA ’S FUTURE Vote FOR Neuphoria 's Board Slate x Transparency & Accountability x Sound Corporate Governance x Value Maximizing Strategic Review x Ability to Develop Pipeline Vote AGAINST Lynx1’s Proposed Slate ï Lack substantive experience in investment banking and financial transact
Slide 25: Thank you
Thank you President and CEO spyros@neuphoriatx.com
Neuphoria Therapeutics — Proxy Contest (November 2025) on 6ix